Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Photobiomodulation as a Potential Treatment for Alzheimer's Disease: A Review Paper

The findings underscore the significant potential of PBM as a safe and effective alternative treatment for Alzheimer's disease, emphasizing the necessity for further research and clinical trials to establish its therapeutic efficacy conclusively.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

This review examines photobiomodulation, a non-invasive use of infrared light, as a possible treatment for Alzheimer's disease, drawing on preclinical studies of its effects on cellular health, cognition and disease progression. The authors describe the approach as safe and effective but state that further research and clinical trials are needed to confirm therapeutic efficacy. The abstract does not report a number of participants or a pooled result.

Who or what was studied
Alzheimer's disease; the abstract refers to preclinical studies but does not specify the populations or models included.
Limits stated in the abstract
The abstract states that further research and clinical trials are needed to establish therapeutic efficacy conclusively, and its evidence base is preclinical.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Alzheimer's disease (AD), the most prevalent form of dementia, is a leading neurodegenerative disorder currently affecting approximately 55 million individuals globally, a number projected to escalate to 139 million by 2050. Despite extensive research spanning several decades, the cure for AD remains at a developing stage. The only existing therapeutic options are limited to symptom management, and are often accompanied by adverse side effects. The pathological features of AD, including the accumulation of beta-amyloid plaques and tau protein tangles, result in progressive neuronal death, synaptic loss, and brain atrophy, leading to significant cognitive decline and a marked reduction in quality of life.

Objective

In light of the shortcomings of existing pharmacological interventions, this review explores the potential of photobiomodulation (PBM) as a non-invasive therapeutic option for AD. PBM employs infrared light to facilitate cellular repair and regeneration, focusing on addressing the disease's underlying biomechanical mechanisms.

Method

This paper presents a comprehensive introduction to the mechanisms of PBM and an analysis of preclinical studies evaluating its impact on cellular health, cognitive function, and disease progression in AD.The review provides a comprehensive overview of the various wavelengths and application methods, evaluating their efficacy in mitigating AD-related symptoms.

Conclusions

The findings underscore the significant potential of PBM as a safe and effective alternative treatment for Alzheimer's disease, emphasizing the necessity for further research and clinical trials to establish its therapeutic efficacy conclusively.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Cognitive decline, Dementia. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies